Lexeo Therapeutics, Inc.
LXEO
$4.85
$0.1853.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 73.68M | 75.52M | 74.09M | 63.94M | 57.76M |
| Gross Profit | -73.68M | -75.52M | -74.09M | -63.94M | -57.76M |
| SG&A Expenses | 49.74M | 40.76M | 31.68M | 29.42M | 24.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.42M | 116.28M | 105.77M | 93.36M | 82.09M |
| Operating Income | -123.42M | -116.28M | -105.77M | -93.36M | -82.09M |
| Income Before Tax | -114.17M | -109.31M | -98.33M | -86.60M | -77.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -114.17 | -109.31 | -98.33 | -86.60 | -77.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.17M | -109.31M | -98.33M | -86.60M | -77.22M |
| EBIT | -123.42M | -116.28M | -105.77M | -93.36M | -82.09M |
| EBITDA | -122.82M | -115.67M | -105.14M | -92.73M | -81.46M |
| EPS Basic | -3.26 | -3.31 | -3.09 | -3.17 | -14.64 |
| Normalized Basic EPS | -2.09 | -2.07 | -1.93 | -1.98 | -9.15 |
| EPS Diluted | -3.26 | -3.31 | -3.09 | -3.17 | -14.64 |
| Normalized Diluted EPS | -2.09 | -2.07 | -1.93 | -1.98 | -9.15 |
| Average Basic Shares Outstanding | 142.83M | 132.26M | 127.12M | 110.48M | 79.05M |
| Average Diluted Shares Outstanding | 142.83M | 132.26M | 127.12M | 110.48M | 79.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |